What is the current stock price of Imunon, Inc. (IMNN)?

As of the latest market data, Imunon, Inc. (IMNN) is trading at $2.92. The stock has seen a loss of -4.58% today.

Does Imunon, Inc. (IMNN) pay a dividend?

Based on current data, Imunon, Inc. does not have a confirmed active dividend policy.

What is the market cap of Imunon, Inc.?

The current market capitalization of Imunon, Inc. (IMNN) is approximately unavailable.

IMNN

Imunon, Inc.·Healthcare

2.92

4.575%(−0.14)

Market Closed

3.25

11.301%(+0.33)

After Hours

Last Updated: — ET

52W L: $2.5252W H: $41.22

IMNN NEWS

seekingalpha.com

Mar 31

Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 31

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J.

globenewswire.com

Mar 25

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months Enrollment in IMUNON's Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT).

globenewswire.com

Mar 24

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.

defenseworld.net

Feb 19

Imunon (IMNN) Projected to Post Quarterly Earnings on Thursday

Imunon (NASDAQ: IMNN - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Imunon to post earnings of ($1.54) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for

defenseworld.net

Feb 13

Head-To-Head Analysis: Pharma Mar (OTCMKTS:PHMMF) vs. Imunon (NASDAQ:IMNN)

Imunon (NASDAQ: IMNN - Get Free Report) and Pharma Mar (OTCMKTS:PHMMF - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Valuation and Earnings This table compares Imunon and Pharma

Company Profile

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1999-03-01

Beta

2.12

Websitewww.imunon.com↗